Semax has been studied in animal models of brain injury and neurodegeneration. In rat models of cerebral ischemia (stroke), Semax treatment administered post-injury reduced infarct volume and improved functional outcomes. The neuroprotective effect was associated with reduced oxidative stress markers and increased expression of anti-apoptotic factors in the affected brain tissue.³

Research in rat models of transient global brain ischemia showed that Semax treatment preserved hippocampal CA1 neurons — a brain region that is particularly vulnerable to ischemic damage and plays a critical role in memory formation.

The neuroprotective research is interpreted in the context of Semax's neurotrophic effects: by upregulating BDNF and NGF, the peptide may create a more resilient neural environment that resists injury-induced cell death.

A series of studies have investigated Semax's effects on gene expression in brain tissue using microarray analysis. Research by Agapova et al. found that Semax modulated the expression of genes involved in immune response, vascular function, and cell survival pathways in rat brain tissue following ischemic injury.⁴

The breadth of gene expression changes suggests that Semax's effects extend beyond direct neurotrophic factor upregulation to include broader neuroprotective and anti-inflammatory transcriptional programs.

An unexpected finding in Semax research has been its immunomodulatory effects. Studies have shown that Semax can influence the expression of genes involved in immune cell function, including cytokine production and immune cell activation. This research has led to investigation of Semax in models where neuroinflammation plays a pathological role.⁵

Selank, a related peptide also available in the OSYRIS catalog, was specifically developed for immunomodulatory and anxiolytic research applications, partly based on these immune-related findings from Semax studies.